Advanced search
1 file | 643.92 KB Add to list

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

(2020) PHARMACEUTICS. 12(2).
Author
Organization
Abstract
Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.
Keywords
MULTIPLE-MYELOMA, BCMA, EXHAUSTION, REMISSIONS, EXPRESSION, MANAGEMENT, LYMPHOMA, GROWTH, 4-1BB, CAR-T cells, immunotherapy, B-cell malignancies, CD19, BCMA

Downloads

  • pharmaceutics-12-00194-v2.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 643.92 KB

Citation

Please use this url to cite or link to this publication:

MLA
Roex, Gils, et al. “Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.” PHARMACEUTICS, vol. 12, no. 2, Mdpi, 2020, doi:10.3390/pharmaceutics12020194.
APA
Roex, G., Feys, T., Beguin, Y., Kerre, T., Poire, X., Lewalle, P., … Anguille, S. (2020). Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. PHARMACEUTICS, 12(2). https://doi.org/10.3390/pharmaceutics12020194
Chicago author-date
Roex, Gils, Tom Feys, Yves Beguin, Tessa Kerre, Xavier Poire, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, and Sebastien Anguille. 2020. “Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.” PHARMACEUTICS 12 (2). https://doi.org/10.3390/pharmaceutics12020194.
Chicago author-date (all authors)
Roex, Gils, Tom Feys, Yves Beguin, Tessa Kerre, Xavier Poire, Philippe Lewalle, Peter Vandenberghe, Dominique Bron, and Sebastien Anguille. 2020. “Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.” PHARMACEUTICS 12 (2). doi:10.3390/pharmaceutics12020194.
Vancouver
1.
Roex G, Feys T, Beguin Y, Kerre T, Poire X, Lewalle P, et al. Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. PHARMACEUTICS. 2020;12(2).
IEEE
[1]
G. Roex et al., “Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data,” PHARMACEUTICS, vol. 12, no. 2, 2020.
@article{8668515,
  abstract     = {Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.},
  articleno    = {194},
  author       = {Roex, Gils and Feys, Tom and Beguin, Yves and Kerre, Tessa and Poire, Xavier and Lewalle, Philippe and Vandenberghe, Peter and Bron, Dominique and Anguille, Sebastien},
  issn         = {1999-4923},
  journal      = {PHARMACEUTICS},
  keywords     = {MULTIPLE-MYELOMA,BCMA,EXHAUSTION,REMISSIONS,EXPRESSION,MANAGEMENT,LYMPHOMA,GROWTH,4-1BB,CAR-T cells,immunotherapy,B-cell malignancies,CD19,BCMA},
  language     = {eng},
  number       = {2},
  pages        = {15},
  publisher    = {Mdpi},
  title        = {Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data},
  url          = {http://dx.doi.org/10.3390/pharmaceutics12020194},
  volume       = {12},
  year         = {2020},
}

Altmetric
View in Altmetric
Web of Science
Times cited: